Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,391 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastrointestinal Malignancies Clear all
Terminated Phase 3 Interventional

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

NCT01309126
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Imprime PGG + cetuximab, Cetuximab
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
44
States / cities
Florence, Alabama • Bentonville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

NCT02013778
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
HCQ
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus

NCT03589443
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Multiplexed heptapeptides
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

NCT00262808
View directory record Official record
Conditions
Colorectal Cancer
Interventions
sargramostim, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Rochester, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated Early Phase 1 Interventional

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

NCT04777708
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma
Interventions
Nanoplexed Poly I:C BO-112, Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 15, 2026, 10:34 AM EDT
Withdrawn Early Phase 1 Interventional

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

NCT04123574
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer
Interventions
Talabostat Mesylate
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

NCT00004190
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated No phase listed Observational

Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer

NCT03137706
View directory record Official record
Conditions
Colon Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Pancreatic Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Laboratory Procedure
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 15, 2026, 10:34 AM EDT
Recruiting No phase listed Observational

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

NCT03250078
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
MRI/MRCP
Diagnostic Test
Lead sponsor
Nuvance Health
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00006389
View directory record Official record
Conditions
Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions
bryostatin 1, cisplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Celiac Plexus Radio-Surgery for Pain Management

NCT03323489
View directory record Official record
Conditions
Advanced Cancer, Pancreas Cancer, Pain
Interventions
Celiac Plexus Radiosurgery
Radiation
Lead sponsor
Dr. Yaacov Lawrence
Government
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Phase 1Phase 2 Interventional

Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer

NCT00005050
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ethynyluracil, fluorouracil, oxaliplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374
View directory record Official record
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 15, 2026, 10:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions
TER-2013, Fulvestrant injection
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated Phase 1Phase 2 Interventional

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550
View directory record Official record
Conditions
Melanoma, Colonic Neoplasms, Breast Neoplasms
Interventions
PD-0325901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 15, 2026, 10:34 AM EDT
Recruiting Not applicable Interventional

Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma

NCT07254910
View directory record Official record
Conditions
CRC Screening, CRC (Colorectal Cancer)
Interventions
Narrative Testimonial Video, v-TCHE Interaction
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
45 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy for Liver Tumors

NCT01347333
View directory record Official record
Conditions
Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions
Stereotactic body radiosurgery, Stereotactic Body Radiotherapy
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 15, 2026, 10:34 AM EDT
Completed No phase listed Observational

EUS-guided Ablation of Pancreatic Cyst Neoplasms

NCT02422147
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
Ablation of PCL
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT05121948
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
Interventions
HC-7366
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 15, 2026, 10:34 AM EDT
Recruiting Phase 2 Interventional

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05686226
View directory record Official record
Conditions
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 15, 2026, 10:34 AM EDT
Recruiting No phase listed Observational

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

NCT03894917
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Comprehensive Geriatric Assessment (CGA)
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 15, 2026, 10:34 AM EDT
Terminated Not applicable Interventional Results available

Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer

NCT06164691
View directory record Official record
Conditions
Pancreatic Neoplasms, Rectal Neoplasms
Interventions
Blue light, Amber light, Ambient White Light
Device · Other
Lead sponsor
Matthew Neal MD
Other
Eligibility
19 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 15, 2026, 10:34 AM EDT
Withdrawn No phase listed Observational

Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

NCT01012804
View directory record Official record
Conditions
Colorectal Cancer
Interventions
western blotting, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Sep 15, 2026, 10:34 AM EDT